CRISPR Therapeutics AG Stock

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-13 EDT 5-day change 1st Jan Change
65.26 USD +0.66% Intraday chart for CRISPR Therapeutics AG +8.84% +4.25%
Sales 2024 * 81.36M 112M Sales 2025 * 332M 456M Capitalization 5.51B 7.56B
Net income 2024 * -448M -616M Net income 2025 * -396M -544M EV / Sales 2024 * 44.4 x
Net cash position 2024 * 1.89B 2.6B Net cash position 2025 * 1.64B 2.25B EV / Sales 2025 * 11.6 x
P/E ratio 2024 *
-11.7 x
P/E ratio 2025 *
-14.4 x
Employees 407
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.94%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer MT
CRISPR Therapeutics Announces Executive Changes CI
Transcript : CRISPR Therapeutics AG Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating MT
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating MT
Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating MT
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating MT
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 Revenue $504,000 MT
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach CI
Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating MT
More news
1 day+0.66%
1 week+8.84%
Current month+21.44%
1 month+17.27%
3 months-12.73%
6 months+6.23%
Current year+4.25%
More quotes
1 week
56.80
Extreme 56.8
67.88
1 month
52.52
Extreme 52.52
67.88
Current year
51.02
Extreme 51.02
91.10
1 year
37.55
Extreme 37.55
91.10
3 years
37.55
Extreme 37.55
169.76
5 years
32.30
Extreme 32.3
220.20
10 years
11.63
Extreme 11.63
220.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 15-07-31
Director of Finance/CFO 40 23-03-13
Chief Tech/Sci/R&D Officer 67 19-09-30
Members of the board TitleAgeSince
Director/Board Member 66 20-06-10
Director/Board Member 47 15-04-28
Director/Board Member 45 15-03-31
More insiders
Date Price Change Volume
24-06-13 65.26 +0.66% 1,767,002
24-06-12 64.83 +4.04% 2,682,466
24-06-11 62.31 +3.87% 1,965,382
24-06-10 59.99 +3.66% 1,102,540
24-06-07 57.87 -3.49% 1,137,788

Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm

More quotes
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
64.83 USD
Average target price
86.57 USD
Spread / Average Target
+33.53%
Consensus